• Evaxion posted a release on EVX-01, outlining plans to present three-year phase 2 efficacy data in advanced melanoma at ESMO 2026.
• Presentation scheduled for Oct. 24, 2026 in Madrid; data include a third-year extension with EVX-01 monotherapy in a subset of patients.
• Prior two-year readout showed 75% ORR in 16 patients, with 92% still responding at two years and no relapses reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607170715PRIMZONEFULLFEED1001213232) on July 17, 2026, and is solely responsible for the information contained therein.